Timolol treats myopic regression

Article

Timolol is successful in treating myopic regression after LASIK and lasts for at least six months.

Timolol is successful in treating myopic regression after LASIK and lasts for at least six months.

Dr Ahmad Shojaei et al., Department of Ophthalmology, Baghiatalah University of Medical Sciences, Tehran, Iran, compiled a prospective, randomized, parallel-controlled, double-masked clinical trial on 90 eyes with myopic regression after LASIK.

Group one consisted of 45 eyes that received timolol 0.5% eye drops and group two who received artificial tears for six months. The main outcome measure was spherical equivalent (SE) six months postoperatively.

SE improved from −1.48 ± 0.99 D in the timolol group before treatment to −0.88 ± 0.91 D and −0.86 ± 0.93 D six months after treatment and six months after timolol discontinuation.

In the artificial tears group the SE outcomes were −1.57 ± 0.67 D, −1.83 ± 0.76 D, and −1.91 ± 0.70 D, respectively. However, in group one there was a 0.26 D decrease in improvement every four months postoperatively.

To read the abstract please visit the American Journal of Ophthalmology.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.